Pfizer Inc. (PFE)
| Market Cap | 129.80B |
| Revenue (ttm) | 62.46B |
| Net Income (ttm) | 7.88B |
| Shares Out | 5.69B |
| EPS (ttm) | 1.38 |
| PE Ratio | 16.50 |
| Forward PE | 7.97 |
| Dividend | $1.72 (7.53%) |
| Ex-Dividend Date | May 9, 2025 |
| Volume | 37,787,149 |
| Open | 22.65 |
| Previous Close | 22.60 |
| Day's Range | 22.45 - 22.85 |
| 52-Week Range | 20.92 - 31.54 |
| Beta | 0.50 |
| Analysts | Hold |
| Price Target | 29.92 (+31.06%) |
| Earnings Date | Apr 29, 2025 |
About PFE
Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular and migraine under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral pr... [Read more]
Financial Performance
In 2024, Pfizer's revenue was $63.63 billion, an increase of 6.84% compared to the previous year's $59.55 billion. Earnings were $8.03 billion, an increase of 279.00%.
Financial StatementsAnalyst Forecast
According to 14 analysts, the average rating for PFE stock is "Hold." The 12-month stock price forecast is $29.92, which is an increase of 31.06% from the latest price.
News
Pfizer's Turnaround Story Is Stronger Than You Think
On April 29, 2025, Pfizer beat consensus EPS estimates for the twelfth consecutive quarter by a wide margin, creating a divergence with its stock price, which continues to move sideways. I was pleasan...
2 Game-Changing Additions To Your Retirement Income Portfolio
Retirement income investing should prioritize risk management, income stability, and capital preservation over aggressive growth strategies. To achieve that, investors tend to allocate high-quality va...
US House panel seeks information from Pfizer over alleged COVID vaccine delay
U.S. lawmakers on Thursday asked Pfizer Inc for information on alleged comments by a former executive suggesting its research executives intentionally delayed clinical trial results of its COVID-19 va...
New allegations about timing of Pfizer Covid vaccine passed to House panel
A former Pfizer scientist said the timing of the 2020 vaccine results “wasn't a coincidence,” according to allegations provided by a rival drugmaker.
Why Pfizer Is Poised For A Strong Comeback: My Top Pick For 2025
Despite trading near decade-low valuations, Pfizer PFE is strategically repositioning itself for substantial long-term growth through its oncology transformation, particularly via the Seagen acquisiti...
Dividend Harvesting Portfolio Week 219: $21,900 Allocated, $2,206.52 In Projected Dividends
I'm bullish on the second half of 2025, expecting further market gains if CPI trends lower and trade talks progress positively. Despite a small portfolio decline this week, my Dividend Harvesting Port...
Dividend Checkup Amid Trump Drug Pricing Order: I Prefer AbbVie Over Pfizer
Ongoing tariff disputes and President Trump's drug pricing order heighten uncertainties for AbbVie Inc. and Pfizer Inc. The more uncertain the time, the more investors should focus on return vectors t...
EU court annuls rejection of bid for EU's von der Leyen vaccine messages with Pfizer
Europe's second-top court on Wednesday dismissed the European Commission's rejection of a New York Times' request to access text messages between its President Ursula von der Leyen and Pfizer CEO Albe...
Pfizer, Eli Lilly, and Other Pharma Stocks Fall. Questions Remain About Trump's Executive Order.
There are significant questions on how the order can be implemented, and if companies can raise prices on already approved drugs, analysts say.
50 Fortune World's Most Admired Companies (FWMAC): 24 "Safer", 1 Ideal Buy
Fortune and Korn Ferry's survey identified the top 50 Most Admired Companies, focusing on criteria like investment value, management quality, and social responsibility. Four dividend-paying companies,...
Trump wants to slash U.S. drug prices with 'most favored nation' policy – here's what to know
President Donald Trump wants to lower U.S. drug costs by linking prices to those paid in other developed countries – a move that experts say could face a challenging path to becoming a reality. Trump...
President Trump's EO to lower drug prices is the beginning of a long process, says Jeff Jonas
Jeff Jonas, Gabelli Funds portfolio manager, joins CNBC's 'Power Lunch' to discuss reactions to President Trump's executive order to lower drug prices, the impact to pharma companies, and more.
Drugmakers are spared worst-case drug pricing scenario for now
Executive order says if companies and the government don't align on tying U.S. drug prices to other countries, the administration will impose its own plan.
Dr. Scott Gottlieb: What to expect from President Trump's executive order to lower drug prices
Scott Gottlieb, former FDA commissioner, joins CNBC's 'Squawk on the Street' to discuss how the White House may plan to cut drug prices.
Trump Declares War On Pharma Drug Pricing, But The Stocks Aren't Tanking - Yet
President Trump has announced today he plans to reduce U.S. drug prices by 30-80% via an Executive Order, targeting Big Pharma's high costs and profits. U.S. drug prices are significantly higher (up t...
Trump says executive order will slash the cost of prescription drugs
President Donald Trump signed an executive order targeting the cost of prescription drugs. Prices will be cut by as much as 80%, and some immediately, he said at a press conference.
Trump Announces Executive Order to Lower Drug Prices
President Donald Trump says he'll sign an executive order that will lower drug prices for Americans. The order aims to align patient costs with lower prices paid abroad, focusing on Medicare and weigh...
White House release details on executive order on drug prices: Here's what to know
CNBC's Eamon Javers reports on the latest news.
Pfizer, Eli Lilly, Other Pharma Stocks Fall as Trump Targets Lower Drug Prices
Trump said he would lower the cost of medicines for Americans by between 30% and 80%.
European pharma stocks follow Asia peers down as Trump moves to cut prices
European drugmakers stocks fell in early trading on Monday after U.S. President Donald Trump said he would sign an executive order on reducing prescription drug and pharmaceutical prices.
Hard To Imagine Retirement Income Portfolio Without These 2 Picks
Typically, investors put a focus on high-yield securities if the goal is to live off from portfolio income streams. These high-yielding securities come from BDC, REIT, MLP, CEF and other value-oriente...
Pressure is still on the pharma sector, says Mizuho's Jared Holz
Jared Holz, Mizuho, joins 'Fast Money' to talk headwinds to the pharma sector.
Dividend Harvesting Portfolio Week 218: $21,800 Allocated, $2,195.04 In Projected Dividends
Earnings season saw strong reports from Microsoft, Apple, Meta, and Amazon, boosting the S&P 500 by 2.75% and the Nasdaq by 2.82%. The Dividend Harvesting Portfolio gained 1.98% this week, with a tota...
March/April Readers Tagged 7 Ideal Dividend Dogs From 12 'Safer' Of 36
Prior to April 30, 2025, my Readers mentioned 36 equities in their comments about my articles. Some bad-news investments (ROgues) mixed with (mostly) FAvorites. Thus, readers spoke-up about their ReFa...